Immuno-Biological Laboratories Co., Ltd. Logo

Immuno-Biological Laboratories Co., Ltd.

Develops and supplies immunological reagents and diagnostics for research and drug discovery.

4570 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
藤岡市中字東田1091番地1
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Immuno-Biological Laboratories Co., Ltd. (IBL) is a research-driven company that develops, manufactures, and supplies immunological research reagents and diagnostics. The company's portfolio includes ELISA kits, specialized antibodies, and cell culture-related products. IBL focuses on key therapeutic areas such as aging, neurodegenerative disorders, kidney diseases, inflammatory diseases, and glucose/lipid metabolism. A notable offering is the LipoSEARCH® lipoprotein analyzing system, which utilizes patented Gel Permeation High-Performance Liquid Chromatography (GP-HPLC) technology. The company collaborates with pharmaceutical partners and research institutions to support drug discovery and the development of novel diagnostics.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Immuno-Biological Laboratories Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-27 06:30
Regulatory News Service
臨時報告書
Japanese 23.0 KB
2025-06-27 02:05
Regulatory News Service
内部統制報告書-第43期(2024/04/01-2025/03/31)
Japanese 25.4 KB
2025-06-27 02:04
Regulatory News Service
確認書
Japanese 8.7 KB
2025-06-27 02:02
Annual Report
有価証券報告書-第43期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2024-11-14 01:04
Regulatory News Service
確認書
Japanese 8.7 KB
2024-11-14 01:02
Interim Report
半期報告書-第43期(2024/04/01-2025/03/31)
Japanese 180.6 KB
2024-06-26 03:44
Regulatory News Service
臨時報告書
Japanese 23.0 KB
2024-06-26 03:41
Regulatory News Service
内部統制報告書-第42期(2023/04/01-2024/03/31)
Japanese 23.7 KB
2024-06-26 03:40
Regulatory News Service
確認書
Japanese 8.7 KB
2024-06-26 03:38
Annual Report
有価証券報告書-第42期(2023/04/01-2024/03/31)
Japanese 1.2 MB
2024-02-14 01:10
Regulatory News Service
確認書
Japanese 8.7 KB
2024-02-14 01:07
Quarterly Report
四半期報告書-第42期第3四半期(2023/10/01-2023/12/31)
Japanese 161.4 KB
2023-11-14 01:02
Regulatory News Service
確認書
Japanese 8.7 KB
2023-11-14 01:01
Quarterly Report
四半期報告書-第42期第2四半期(2023/07/01-2023/09/30)
Japanese 190.6 KB
2023-08-14 02:08
Regulatory News Service
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all Immuno-Biological Laboratories Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Immuno-Biological Laboratories Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
BioGaia Logo
Develops and commercializes clinically proven probiotics for digestive health across all life stages.
Sweden BIOG
Bio-Gate AG Logo
Develops antimicrobial & antiviral tech for medical, cosmetic, & industrial products.
Germany BIG1
BioInvent International Logo
Develops first-in-class immuno-modulatory antibodies for cancer therapy.
Sweden BINV
BioLineRx Ltd. Logo
Biopharma firm developing and commercializing therapies for cancer and rare diseases.
Israel BLRX
BioMaxima S.A. Logo
Manufacturer of IVD solutions including tests, reagents, and equipment for medical labs.
Poland BMX
bioMérieux Logo
Provides in vitro diagnostic solutions for clinical and industrial microbiology.
France BIM
BioPorto Logo
IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.
Denmark BIOPOR
Biosergen AB Logo
Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.
Sweden BIOSGN
Biosynex Logo
European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.
France ALBIO
Biotest AG Logo
Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.
Germany BIO3

Talk to a Data Expert

Have a question? We'll get back to you promptly.